Lilly’s Retatrutide Outperforms Ozempic in Blood Sugar Control and Weight Loss

Eli Lilly announced Wednesday that its investigational therapy outperformed Novo Nordisk’s Ozempic in lowering blood glucose and promoting weight loss during a large-scale diabetes trial, strengthening the competitive profile of its candidate.

In the head-to-head evaluation, patients receiving the highest dose of Lilly’s retatrutide achieved a 2.2 percentage-point reduction in A1c, a key measure of blood sugar control, after 80 weeks. Patients on Ozempic saw a 1.8 percentage-point reduction over the same period.

Participants on the highest retatrutide dose also lost 20.9% of their body weight—a significant result given that individuals with diabetes typically experience minimal weight loss from medication. Those taking Ozempic lost 9.4% of their weight. These findings are based on participants who remained on treatment, not the entire study population.

Source link